Introduction {#S1}
============

The physiologically unusual stimulation of T cells by donor antigen-presenting cells (APCs) has been called "direct" recognition, whereas stimulation by self-APCs, presenting peptides of donor origin, has been called "indirect" recognition. Direct recognition has been believed to be the major pathway involved in allograft rejection due to three basic observations, namely, (1) direct stimulation is very strong in a primary allogenic mixed lymphocyte reaction, (2) depletion of donor APCs can sometimes prolong allograft survival, and (3) donor major histocompatibility complex (MHC) antigens (Ags) are more important than minor Ags in causing graft rejection ([@B1]). Matching for MHC Ags achieves better allograft survival. Lechler and Batchelor showed the importance of MHC class II matching compared to MHC class I matching at least in the long-term survival ([@B2]). However, there are several remarkable reports of consequences of T cells responding via the indirect pathway. These reports showed the indirect pathway (a) helps for priming alloreactive CD8 T cells ([@B3], [@B4]), (b) is essential for tolerance induction in some models ([@B5], [@B6]), and (c) is involved in chronic transplant rejection ([@B7], [@B8]). In addition, several papers have shown the importance of an indirect response in allograft rejection ([@B1], [@B3], [@B9], [@B10]). Indirect allorecognition contributes not only to acute graft rejection ([@B2], [@B9]) but also possibly to the continuing response to the allograft in the long term after transplantation ([@B11]). Previously, we tested the role of costimulatory blockade for prolonging allograft survival with using class II-deficient mice when only one or the other pathway of graft rejection was available. We found that to achieve long-term survival after costimulatory blockade requires that the recipient expresses MHC class II molecules ([@B12]). This result indicated that indefinite cardiac transplant survival could not be achieved in the absence of an intact indirect pathway. These results are consistent with the fact that at least a component of the regulatory T cell (Treg) response must involve recognition of peptides of donor Ags presented by recipient MHC molecules ([@B13]). Authors also mentioned that linked suppression can also be induced through the indirect pathway. However, little work seems to have addressed their direct role in transplantation. Therefore, in the current study, we tested whether the Tregs that transfer tolerance have the capacity for linked suppression.

Methods and Results {#S2}
===================

First, we made B10.D2 (H-2^d^) mice tolerant to B6 (H-2^b^) with costimulatory blockade \[250 μg intraperitoneal (i.p.) injection of MR1 on day 0 and 250 μg i.p. injection of CTLA-4 Ig on day 2\] (Figure [1](#F1){ref-type="fig"}A). At least 8 weeks later, a second heart transplant was performed to a new B10.D2 recipient who had been irradiated with 450 cGy. All recipient received intravenous (i.v.) injection of naive 40 × 10^6^ splenocytes + 40 × 10^6^ splenocytes that are taken from the tolerant mice (toleralized splenocytes: Tol.) significantly prolonged graft survival compared to recipient received only naive splenocyte (12 ± 1 days compared to \>100, *p* \< 0.001) (Figure [1](#F1){ref-type="fig"}B). After these results, we considered linkage of Tregs. Next, we performed a second transplant from B6 mice to irradiated B10.D2 mice. The second donors express the same MHC and minor Ags as the first graft or B10.BR heart grafts differ from the first graft in their MHC Ags or (B6 × B10.BR) F1 mice, which express both H-2^b^ and H-2^k^ Ags. After transplant, the mice received i.v. injection of naive and toleralized splenocytes. All B6 hearts survived over 100 days. But B10.BR hearts expressing third party MHC were rejected by 23 days (Figure [1](#F1){ref-type="fig"}C). (B10.BR × B6) F1 hearts expressing third party MHC with tolerant MHC showed 80% survival of over 100 days; however, CAV was observed in some specimen. The institutional subcommittee on research animal care at Massachusetts General Hospital approved all animal experiments.

![**(A) Allograft survival in B10.D2 recipients**: (\>100 days, *n* = 5, *p* = 0.0017 compared to control: 16.2 days, *n* = 5). **(B)** **Adoptive transfer model**: naive splenocytes transfer (*n* = 6), both naive and Tol. splenocytes transfer (100 days, *n* = 6, *p* = 0.0007). **(C)** **Linkage model**: B6 hearts (\>100 days), B10.BR hearts (\~23 days, *n* = 6, *p* = 0.0006) (B6 × B10.BR) F1 (\>100 days, *n* = 4/5, *p* = 0.0044).](fimmu-07-00082-g001){#F1}

Discussion {#S3}
==========

Linked suppression has often been associated with Tregs, and its mechanisms must be important ones, as tolerance can be extended to whole MHC disparities when applied to cardiac transplantation. Tolerance was extended to third party transplant Ags, even to MHC-encoded Ags, provided they are expressed on the same graft as the tolerated Ags in some models ([@B14]--[@B17]). Thus, its mechanism of immunoregulation in transplantation is very important. In addition, understanding interactions between linked suppression and Tregs can potentially be great advantage in the setting of transplantation to propagate the development of specific unresponsiveness once the process has been initiated.

Our preliminary data showed that Tregs suppress the graft rejection in an Ag-specific manner and Tregs generated in the face of MHC disparities suppress the rejection of grafts expressing third party MHC along with tolerant MHC.

Conclusion {#S4}
==========

The very limited comparison in this experiment will determine whether the patterns of gene expression can reliably distinguish a regulatory population from one that promotes rejection.
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